US Stock MarketDetailed Quotes
RPHM Reneo Pharmaceuticals
- 1.670
- +0.020+1.21%
Close Apr 26 16:00 ET
- 1.670
- 0.0000.00%
Post 16:20 ET
55.81MMarket Cap-662P/E (TTM)
1.710High1.660Low115.22KVolume1.710Open1.650Pre Close193.05KTurnover0.92%Turnover RatioLossP/E (Static)33.42MShares10.98052wk High0.63P/B21.00MFloat Cap0.98052wk Low--Dividend TTM12.58MShs Float17.180Historical High--Div YieldTTM3.01%Amplitude0.980Historical Low1.675Avg Price1Lot Size
Reneo Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -34.46%-63.68M | -26.52%-19.75M | -73.87%-18.77M | -34.78%-16.11M | -0.54%-9.05M | -24.69%-47.36M | -55.80%-15.61M | -11.60%-10.79M | -23.25%-11.96M | -4.77%-9M |
| Net income from continuing operations | -48.95%-77.39M | -73.19%-23.55M | -47.58%-19.2M | -58.63%-19.53M | -15.89%-15.11M | -30.64%-51.96M | -28.22%-13.6M | -2.14%-13.01M | -33.59%-12.31M | -80.75%-13.04M |
| Operating gains losses | ---- | ---- | --2K | --0 | --3K | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 93.18%170K | 76.00%44K | 95.45%43K | 90.91%42K | 115.79%41K | 76.00%88K | 47.06%25K | 69.23%22K | 120.00%22K | 90.00%19K |
| Other non cash items | 1,180.77%333K | -1,707.58%-1.06M | 183.33%306K | 601.04%673K | 270.08%415K | --26K | --66K | --108K | --96K | ---244K |
| Change In working capital | 1,174.04%12.22M | 251.84%4.08M | -84.72%189K | 467.25%2.74M | 65.28%5.21M | 134.25%959K | -144.05%-2.69M | -35.03%1.24M | 57.31%-745K | 269.75%3.15M |
| -Change in prepaid assets | 73.58%1.52M | -86.94%-501K | 100.41%483K | 62.93%-410K | -2.93%1.95M | 118.64%878K | 76.37%-268K | 121.52%241K | 27.62%-1.11M | 316.47%2.01M |
| -Change in payables and accrued expense | 2,046.33%11.12M | 298.75%4.61M | -116.46%-183K | 593.05%3.29M | 171.62%3.4M | -70.90%518K | -6,344.44%-2.32M | -62.68%1.11M | 300.42%475K | 234.95%1.25M |
| -Change in other current liabilities | 2.97%-424K | 69.70%-30K | 4.31%-111K | -28.07%-146K | -26.85%-137K | -433.59%-437K | -243.48%-99K | -363.64%-116K | -670.00%-114K | -5,300.00%-108K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -34.46%-63.68M | -26.52%-19.75M | -73.87%-18.77M | -34.78%-16.11M | -0.54%-9.05M | -24.69%-47.36M | -55.80%-15.61M | -11.60%-10.79M | -23.25%-11.96M | -4.77%-9M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 118.19%10.52M | 247.77%39.78M | 146.77%21.25M | -859.78%-69.01M | 241.02%18.51M | -147.44%-57.84M | -430.15%-26.92M | -907.65%-45.44M | 133.65%9.08M | 21,808.00%5.43M |
| Net PPE purchase and sale | 36.13%-221K | 90.00%-25K | 32.14%-19K | 79.17%-5K | -290.91%-172K | -74.75%-346K | -177.78%-250K | 63.64%-28K | -300.00%-24K | -76.00%-44K |
| Net investment purchase and sale | 118.68%10.74M | 249.25%39.8M | 146.84%21.27M | -857.72%-69.01M | 241.42%18.68M | -148.06%-57.5M | -423.51%-26.67M | -924.53%-45.41M | 133.74%9.11M | --5.47M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 118.19%10.52M | 247.77%39.78M | 146.77%21.25M | -859.78%-69.01M | 241.02%18.51M | -147.44%-57.84M | -430.15%-26.92M | -907.65%-45.44M | 133.65%9.08M | 21,808.00%5.43M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 12,822.51%60.87M | -1,370.15%-4.13M | 78.35%173K | 148,297.67%63.81M | 16,716.67%1.01M | -99.64%471K | 173.11%325K | -56.31%97K | -99.95%43K | -99.99%6K |
| Net common stock issuance | 31,058.03%60.14M | -2,381.35%-4.4M | --0 | 1,058,916.67%63.53M | 16,716.67%1.01M | -99.77%193K | 765.52%193K | --0 | ---6K | --6K |
| Proceeds from stock option exercised by employees | 162.59%730K | 108.33%275K | 78.35%173K | ---- | ---- | -50.00%278K | -11.41%132K | -55.91%97K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 12,822.51%60.87M | -1,370.15%-4.13M | 78.35%173K | 148,297.67%63.81M | 16,716.67%1.01M | -99.64%471K | 173.11%325K | -56.31%97K | -99.95%43K | -99.99%6K |
| Net cash flow | ||||||||||
| Beginning cash position | -84.01%19.93M | -81.11%11.74M | -92.32%9.08M | -74.90%30.4M | -84.01%19.93M | 132.52%124.66M | -50.85%62.13M | -15.75%118.26M | 32.75%121.09M | 132.52%124.66M |
| Current changes in cash | 107.36%7.71M | 137.66%15.9M | 104.73%2.66M | -653.14%-21.31M | 393.55%10.47M | -247.41%-104.73M | -2,313.09%-42.21M | -302.12%-56.13M | -105.76%-2.83M | -109.48%-3.57M |
| End cash Position | 38.67%27.63M | 38.67%27.63M | -81.11%11.74M | -92.32%9.08M | -74.90%30.4M | -84.01%19.93M | -84.01%19.93M | -50.85%62.13M | -15.75%118.26M | 32.75%121.09M |
| Free cash flow | -33.95%-63.9M | -24.68%-19.78M | -73.59%-18.79M | -34.55%-16.12M | -1.96%-9.22M | -24.95%-47.71M | -56.89%-15.86M | -11.01%-10.82M | -23.42%-11.98M | -4.98%-9.04M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg